Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
06/2002
06/04/2002US6399754 Sugar modified oligonucleotides
06/04/2002US6399753 A dna encoding an amino acid sequence; diagnosis and therapy for vascular injury, strokes, atherosclerosis and restenosis
06/04/2002US6399588 Cancer treatment method utilizing plasmids suitable for IL-2 expression
06/04/2002US6399587 In situ transferring of a gene
06/04/2002US6399585 In Utero treatment of CFTR-related deficiencies
06/04/2002US6399584 Pharmaceutical composition containing ezrin mutated on tyrosine 353
06/04/2002US6399573 Interleukin-1 receptor antagonist beta (IL-1rabeta)
06/04/2002US6399385 Conjugating a genetically engineered virus with polyethylene glycol at ambient temperature for improved gene expression
06/04/2002US6399384 Conditional immortalization of cells
06/04/2002US6399383 A genetically engineered viral vector; gene therapy for promoting hair growth or alteration of hair color
06/04/2002US6399379 Antisense modulation of interleukin 12 p35 subunit expression
06/04/2002US6399376 Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
06/04/2002US6399370 Compositions and methods for use of defensin
06/04/2002US6399369 Multipotent neural stem cell cDNA libraries
06/04/2002US6399362 Includes biological source material such as nucleic acids and a dispensing device for spray of dispersed particles
06/04/2002US6399343 Amino acid sequence of gene from streptococcus; drug screening for bactericides
06/04/2002US6399328 Amino acid sequence; hybridization probes; amplification primers; anticarcinogenic agents; antitumor agents
06/04/2002US6399316 PACAP receptor protein, method for preparing said protein, and use thereof
06/04/2002US6399300 Recombinant embryonic cardiomyocyte cell having two constructs which are selectable marker genes under control of separate promoters; gene therapy; drug screening
06/04/2002US6399297 Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)
06/04/2002US6399075 Peptide sequences for viricides
06/04/2002US6399067 Methods and compositions for impairing multiplication of HIV-1
06/04/2002US6399065 Methods for modulating SLAM-expressing T cells
06/04/2002US6398816 Genetic engineering of cells to enhance healing and tissue regeneration
06/04/2002US6398757 Gene therapeutic treatment of blood vessel associated disorders
06/04/2002US6397849 Methods of ophthalmic administration
06/04/2002CA2011450C Recombinant b-chain of the il-2 receptor
05/2002
05/30/2002WO2002042776A2 Compositions and methods relating to prostate specific genes and proteins
05/30/2002WO2002042772A1 TRIPEPTIDE OF FCηRIIA
05/30/2002WO2002042482A2 Functional lentiviral vector from an mlv-based backbone
05/30/2002WO2002042481A1 Paramyxovirus vector encoding angiogenesis gene and utilization thereof
05/30/2002WO2002042480A2 Modified vaccinia ankara virus variant
05/30/2002WO2002042468A2 Glycosyltransferase vectors for treating cancer
05/30/2002WO2002042455A2 Modifier of organelle metalbolism
05/30/2002WO2002042454A2 Gene involved in schizophrenia
05/30/2002WO2002042452A2 Adapter protein and gene encoding it
05/30/2002WO2002042447A2 Surface transfection and expression procedure
05/30/2002WO2002042426A2 Carrier system for specific artery wall gene delivery
05/30/2002WO2002042423A2 Antisense modulation of src-2 expression
05/30/2002WO2002042332A2 Truncated cd200
05/30/2002WO2002042328A2 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
05/30/2002WO2002042325A2 Cyp1b1 nucleic acids and methods of use
05/30/2002WO2002042317A2 Method of separating extra-chromosomal dna from other cellular components
05/30/2002WO2002042316A2 Pna analogues
05/30/2002WO2002041922A1 Method of regulating the activity of expression product of gene transferred into living body
05/30/2002WO2002041911A2 Use of fgf-19 for inhibiting angiogenesis
05/30/2002WO2002028440B1 Methods and compositions for modulating t cell activation and uses thereof
05/30/2002WO2002018438A9 Modified proteins, isolated novel peptides, and uses thereof
05/30/2002WO2002011785A3 Manipulation of arterial-venous identity
05/30/2002WO2002010346A3 Insulin producing cell-line obtained by electrofusion
05/30/2002WO2002005792A3 Use of matrix metalloprotease inhibitors for the treatment of cancer
05/30/2002WO2002002756A3 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis
05/30/2002WO2001098482A3 Liver-specific gene expression cassettes, and methods of use
05/30/2002WO2001092580A3 Lyophilizable and enhanced compacted nucleic acids
05/30/2002WO2001092565A8 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
05/30/2002WO2001091789A3 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
05/30/2002WO2001087978A3 Human abc transporter and its use
05/30/2002WO2001087934A3 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
05/30/2002WO2001068888A3 Production of chimeric capsid vectors
05/30/2002WO2001066760A3 Novel human kinase interacting protein and polynucleotides encoding the same
05/30/2002WO2001066746A3 G-protein coupled receptor related polypeptides
05/30/2002WO2001064877A3 Human schizophrenia gene
05/30/2002WO2001048187A3 A molecular switch for regulating mammalian gene expression
05/30/2002WO2001045731A9 Particulate drug-containing products and method of manufacture
05/30/2002WO2001043759A3 Use of 11cby popypeptides and polynuceotides
05/30/2002WO2000078952A8 Human rna metabolism proteins (rmep)
05/30/2002WO2000052205A8 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE
05/30/2002US20020065397 Protecting therapeutic compositions from host-mediated inactivation
05/30/2002US20020065395 Polypeptide for use as diagnostic tool in screening bactericides
05/30/2002US20020065243 Controlled activation of DNA molecules for gene therapy using a heat- or light-inducible promoter; levels of gene expression modulated by antibiotic concentrations; side- effects reduction; breast/ovarian/prostate cancers; tumors
05/30/2002US20020065241 A recombinant polynucleotide of first polynucleotides coding an antigenic peptide and are operatively linked to each other to enhance translation of the polynucleotides to the peptides and binding to MHC; cancer vaccine
05/30/2002US20020065240 Gene therapy for stimulation of angiogenesis
05/30/2002US20020065239 Antidiabetic agents; obesity and diabetic-related conditions; administration of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modififying proteins
05/30/2002US20020065238 EPO primary response gene, EPRG3pt
05/30/2002US20020065236 Reducing the inflammatory response to gene therapy by modifying a plasmid or viral vector to reduce or eliminate the immunostimulatory response by removing a CpG (cytosine-guanosine dinucleotide) motif or methylating a CpG motif
05/30/2002US20020065226 Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
05/30/2002US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins
05/30/2002US20020065213 Increasing the duration of expression of a delivered gene in target cells by delivering a gene encoding a cellular retention activity and nuclear binding sequence to target cells before or during gene of interest delivery
05/30/2002US20020065212 Methods of treating disease using sertoli cells and allografts or xenografts
05/30/2002US20020064877 Methods of producing and using a human microglial cell line
05/30/2002US20020064876 Genetically engineering cells of skin; obtain cells, transform with expression vector, monitor cells for preferential phenotypes
05/30/2002US20020064870 Replication defective microorganismal vectors for use in the treatment of vision defects
05/30/2002US20020064862 Preventing viral replication in cells; obtain cells, incubate with viricide, monitor cells for reduced viral activity
05/30/2002US20020064859 Nuclelotide sequences coding heterologous protein for use in the treatment of cancer, infections, genetic and immunological disorder
05/30/2002US20020064848 Novel histidinol dehydrogenase
05/30/2002US20020064833 Nucleotide sequences for use in the treatment of drug abuse and drug dependence
05/30/2002US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies
05/30/2002US20020064823 Nucleotide sequences which code binding protein for use in human therapeutics and gene therapy
05/30/2002US20020064818 Nucleotide sequences coding preferential polypeptide; for use in diagnosis and treatment of cancer, nervous system, inflammatory and immunological disorders
05/30/2002US20020064812 Plasmid for use in the treatment of blood disorders
05/30/2002US20020064786 Cancer diagnosis and therapy based on mutations in TGF-beta receptors
05/30/2002US20020064553 Large liposome composition not increasing ldl levels and method of treating atherosclerosis related thereto
05/30/2002US20020064525 Anti-IgE vaccines
05/30/2002US20020064521 Nucleic acids coding for both A and B chains of human p53, human leukocyte antigen(HLA) restricted murine T-cell receptor (TCR); transformed CD8+ cytotoxic T lymphocytes for immunotherapy of tumors that over-express p53
05/30/2002US20020064520 Targeted artificial gene delivery
05/30/2002US20020064519 Administering non-autologous (allogeneic) mesenchymal stem cells (they are "invisible" to the immune system) to promote hematopoietic or progenitor cell engraftment; use as host cells in gene therapy or in tissue repair
05/30/2002US20020064517 Applying a fibrin gel to the cell to be transformed to entrap a nucleic acid being used, transforming the cell; gene therapy; kits
05/30/2002US20020062835 Methods of modulating hair growth
05/30/2002CA2429856A1 Adapter protein and gene encoding it
05/30/2002CA2429579A1 Truncated cd200